Where Will Quantum Computing Stock Be in 1 Year?

Quantum Computing Inc. (QCI / QUBT) has begun shipping photonic chips after opening its first foundry in May but generated only $484,000 of revenue in the first nine months of 2025 and is forecast to record $777,000 in revenue and a net loss of nearly $24 million for the full year. With a $2.7 billion market cap and trading at ~3,481x 2025 sales, analysts expect 2026 revenue to rise to $2.1 million (+169%) while losses widen to $40.5 million; the company won’t mass-produce until a planned second fab and will likely need additional capital, leaving the equity highly speculative and vulnerable to dilution and competitive pressures from IonQ, Rigetti, Xanadu and PsiQuantum.

Analysis

Market structure: Photonic players (QUBT, Xanadu, PsiQuantum) and foundry/tooling suppliers gain strategic optionality if photonics scales; incumbent superconducting/ion vendors (IBM, IONQ, RGTI) face competitive pressure but retain pricing power via installed ecosystems. Current pricing shows extreme speculative premium for QUBT (3,481x 2025 sales) implying market expects either rapid scale or transformational contracts; absent those, supply-demand stays supply-constrained (limited wafers, external optical subsystems) with demand concentrated in gov/research niches.

Risk assessment: Low-probability/high-impact tails include (1) government/defense contract or acquisition that could re-rate QUBT +3x–10x within 3–12 months, and (2) cash exhaustion/dilution or failed fab scale leading to >90% equity loss within 12–24 months. Near-term (days–weeks) risks center on financing announcements and demo volatility; medium-term (6–18 months) hinge on Dirac-3 performance metrics and small-batch yields; long-term (2–4 years) on second-fab funding and mass-production economics.

Trade implications: Primary actionable is biased negative on QUBT: short-equity exposure size 1–2% portfolio or buy 12-month puts (see strikes below), with pair trades long IONQ (or selective IBM) vs short QUBT to capture relative mispricing (IONQ ~159x sales vs QUBT 3,481x). Sector rotation: trim small-cap quantum/photonic long exposure by 50% and reallocate into larger diversified tech (IBM) and select foundry/equipment suppliers that would benefit from any photonics scale-up.

Contrarian angles: Consensus downplays that photonics can leverage existing CMOS fabs — if QUBT secures a strategic foundry partner or shows Dirac-3 error rates dropping toward parity (e.g., two‑order magnitude reduction) the stock could re-rate sharply; this is low-probability but high-upside. Conversely, the market may be underpricing imminent dilution: treat existing share count increases >10% as a sell/short trigger and monitor wafer-starts, Dirac cloud hours, and disclosed gross yields as leading indicators.

Key Decisions for Investors

• Establish a tactical short position in QUBT equal to 1–2% of portfolio (or synthetic via borrow) with a 6–12 month horizon; target core profit objective $6 (≈50% downside), tighten/close if QUBT > $20 on sustained volume or if company announces a contract >= $50M within 10 trading days.
• Implement a pair trade: go long IONQ equal-dollar and short QUBT for a 6–12 month hold (size each 1% of portfolio). Rationale: relative valuation gap (IONQ ~159x vs QUBT ~3,481x sales) and more diversified commercial revenue path in near term.
• Buy a 12-month QUBT put spread to hedge tail risk: buy $6 strike / sell $3 strike puts (or nearest available strikes) sized to 0.5% portfolio; this caps downside cost while capturing >50% downside if QUBT collapses toward penny-stock levels.
• Reduce total small-cap quantum/photonic equity exposure by 50% and redeploy into (a) IBM up to 1–2% as defensive tech exposure and (b) select semiconductor equipment/foundry names (ASML, LRCX) up to 1% to play fabrication scale-up; rebalance on concrete KPIs: monthly wafer starts, Dirac cloud hours, or announced second-fab financing >= $200M.